These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37702136)

  • 41. Complete dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling pathways underlies decreased cytokine production and increased susceptibility to Streptococcus pneumoniae infection in IRAK4 kinase-inactive mice.
    Pennini ME; Perkins DJ; Salazar AM; Lipsky M; Vogel SN
    J Immunol; 2013 Jan; 190(1):307-16. PubMed ID: 23209321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells.
    Katsuyama E; Miyamoto H; Kobayashi T; Sato Y; Hao W; Kanagawa H; Fujie A; Tando T; Watanabe R; Morita M; Miyamoto K; Niki Y; Morioka H; Matsumoto M; Toyama Y; Miyamoto T
    J Biol Chem; 2015 Jan; 290(2):716-26. PubMed ID: 25404736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
    Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
    J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-1 Receptor-Associated Kinase 1/4 as a Novel Target for Inhibiting Neointimal Formation After Carotid Balloon Injury.
    Bai S; Li D; Zhou Z; Cao J; Xu T; Zhang X; Wang Y; Guo J; Zhang Y
    J Atheroscler Thromb; 2015; 22(12):1317-37. PubMed ID: 26310493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
    Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
    Elife; 2022 Aug; 11():. PubMed ID: 36040792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
    Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
    Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
    Winkler A; Sun W; De S; Jiao A; Sharif MN; Symanowicz PT; Athale S; Shin JH; Wang J; Jacobson BA; Ramsey SJ; Dower K; Andreyeva T; Liu H; Hegen M; Homer BL; Brodfuehrer J; Tilley M; Gilbert SA; Danto SI; Beebe JJ; Barnes BJ; Pascual V; Lin LL; Kilty I; Fleming M; Rao VR
    Arthritis Rheumatol; 2021 Dec; 73(12):2206-2218. PubMed ID: 34423919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting IRAK4 for Degradation with PROTACs.
    Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA
    ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in the Toll-Like Receptor 4 (TLR4) Signaling Pathway.
    Shi M; Deng Y; Yu H; Xu L; Shi C; Chen J; Li G; Du Y; Wang YG
    Mediators Inflamm; 2019; 2019():7634761. PubMed ID: 31611735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis.
    Biancheri P; Foster MR; Fyfe MC; MacDonald TT; Sirohi S; Solanke Y; Wood E; Rowley A; Webber S; Walshe CA
    Inflamm Bowel Dis; 2016 Jun; 22(6):1306-15. PubMed ID: 27104822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IRAK4 activity controls immune responses to intracellular bacteria Listeria monocytogenes and Mycobacterium smegmatis.
    Pattabiraman G; Murphy M; Agliano F; Karlinsey K; Medvedev AE
    J Leukoc Biol; 2018 Oct; 104(4):811-820. PubMed ID: 29749650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of adenovirus-mediated knockdown of IRAK4 on synovitis in the osteoarthritis rabbit model.
    Li M; Li H; Ran X; Yin H; Luo X; Chen Z
    Arthritis Res Ther; 2021 Dec; 23(1):294. PubMed ID: 34863246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells.
    Corzo CA; Varfolomeev E; Setiadi AF; Francis R; Klabunde S; Senger K; Sujatha-Bhaskar S; Drobnick J; Do S; Suto E; Huang Z; Eastham-Anderson J; Katewa A; Pang J; Domeyer M; Dela Cruz C; Paler-Martinez A; Lau VWC; Hadadianpour A; Ramirez-Carrozi V; Sun Y; Bao K; Xu D; Hunley E; Brightbill HD; Warming S; Roose-Girma M; Wong A; Tam L; Emson CL; Crawford JJ; Young WB; Pappu R; McKenzie BS; Asghari V; Vucic D; Hackney JA; Austin CD; Lee WP; Lekkerkerker A; Ghilardi N; Bryan MC; Kiefer JR; Townsend MJ; Zarrin AA
    Sci Signal; 2020 Jun; 13(634):. PubMed ID: 32487715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of intraplantar morphine on paw edema and pain-related behaviour in a rat model of repeated acute inflammation.
    Perrot S; Guilbaud G; Kayser V
    Pain; 1999 Nov; 83(2):249-57. PubMed ID: 10534597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Crystal structure of human IRAK1.
    Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.
    Staschke KA; Dong S; Saha J; Zhao J; Brooks NA; Hepburn DL; Xia J; Gulen MF; Kang Z; Altuntas CZ; Tuohy VK; Gilmour R; Li X; Na S
    J Immunol; 2009 Jul; 183(1):568-77. PubMed ID: 19542468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transgenic mice overexpressing human ALOX15 under the control of the aP2 promoter are partly protected in the complete Freund's adjuvant-induced paw inflammation model.
    Heydeck D; Kakularam KR; Labuz D; Machelska H; Rohwer N; Weylandt K; Kuhn H
    Inflamm Res; 2023 Aug; 72(8):1649-1664. PubMed ID: 37498393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
    Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
    Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.